Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Core Insights - Relay Therapeutics, Inc. is a clinical-stage company focused on developing small molecule precision medicine for cancer and genetic diseases [2] - The company will participate in two fireside chats in September 2025, which will be available for live streaming and archived for 30 days [1] Company Overview - Relay Therapeutics utilizes its Dynamo platform to address challenging protein targets, aiming to create impactful therapies [2] - The lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in Phase 3 trials for HR+/HER2- metastatic breast cancer [2] - RLY-2608 is also being explored for PI3Kα-driven vascular malformations and the company has additional research programs targeting NRAS-driven solid tumors and Fabry disease [2] Upcoming Events - Relay Therapeutics will present at the Wells Fargo Healthcare Conference on September 4, 2025, at 2:15 p.m. ET [3] - The company will also participate in the Morgan Stanley 23rd Annual Global Conference on September 10, 2025, at 11:30 a.m. ET [3]